Global Hematology Drugs Market Report 2017; New Report Launched
Increase in number of Hematology disease drug approvals from the regulatory bodies such as FDA in the US and EMA in EU is an emerging trend in the market. For instance, in June 2017, Novo Nordisk received FDA approval for its Rebinyn (Coagulation Factor IX (Recombinant), GlycoPEGylated) that is used in the treatment of hemophilia B.
View full press release